Recent Updates
Recently added Catalysts
ATRC Positive Sentiment Score: 75/100

AtriCure Reports Second Quarter 2026 Financial Results

Thursday, July 23, 2026 1 min read
Key Takeaway: AtriCure, Inc. has reported its financial results for the second quarter of 2026, highlighting healthy growth and a notable increase in profitability. CEO Michael Carrel emphasized the effectiveness of their innovative technologies in surgical treatments for atrial fibrillation and related areas. The company continues to strengthen its position in the market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Healthy growth reported in second quarter results.
  • Significant increase in profitability.
  • Innovative technologies are proving effective.

Full Press Release Details

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu

Frequently Asked Questions

What were AtriCure's financial results for Q2 2026?

AtriCure reported healthy growth and a significant increase in profitability.

Who is the CEO of AtriCure?

Michael Carrel is the President and Chief Executive Officer of AtriCure.

What technologies does AtriCure focus on?

AtriCure specializes in surgical treatments for atrial fibrillation and pain management.

Tags: ATRC Viatris Investor Conferences Healthcare AtriCure financial results Q2 2026 atrial fibrillation surgical treatments
Last updated: Jul 23, 2026

Biotech snapshot

Cash runway
$146M liquidity · $1M/mo burn
~107 mo
Minimal dilution risk
Lead asset
AtriCure LAA Exclusion SystemPhase 2
Left Atrial Appendage Exclusion →